Electronic health record derived-impact of COVID-19 on myasthenia gravis
As effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerge, it is important to have timely real-word data that guides immunization prioritization for our patients and especially possibly more vulnerable neuromuscular populations [1]. Recent data have shown that patients with chronic autoimmune neuromuscular disorders who are on immunosuppression were more likely to require hospitalization with Coronavirus Disease 2019 (COVID-19) [2]. Similarly, recent preliminary data published from the COVID-19 Associated Risks and Effects in Myasthenia Gravis (CARE-MG) registry, demonstrated a mortality of 24% and MG relapse rate of 40% among 91 patients [3].
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Bhaskar Roy, Sukanthi Kovvuru, Krishna Nalleballe, Sanjeeva Reddy Onteddu, Richard J. Nowak Tags: Letter to the Editor Source Type: research
More News: Autoimmune Disease | Brain | Coronavirus | COVID-19 | Electronic Health Records (EHR) | Myasthenia Gravis | Neurology | Respiratory Medicine | SARS | Vaccines